AMNEAL PHARMACEUTICALS, INC. Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax
AMNEAL PHARMACEUTICALS, INC. (AMRX) reported Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax of $6.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax · last filed 2026-08-06
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-06-30 was $6.06M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2026-03-31 was $4.39M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-12-31 was $588.00K, a 96.73% decline year-over-year.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for the quarter ending 2025-09-30 was -$3.53M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2025 was -$22.42M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2024 was -$1.17M.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2023 was -$48.50M, a 149.97% decline from fiscal 2022.
- AMNEAL PHARMACEUTICALS, INC. other comprehensive income (loss), cash flow hedge, gain (loss), before reclassification, after tax for fiscal 2022 was $97.06M, a 128.75% increase from fiscal 2021.
| Period end | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 3 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 6 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 9 month | Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $6.06M 10-Q · filed 2026-08-06 | $10.46M 10-Q · filed 2026-08-06 | $11.04M derived: sum of 3 quarters · filed 2026-08-06 | $7.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.39M 10-Q · filed 2026-05-07 | $4.98M derived: sum of 2 quarters · filed 2026-05-07 | $1.46M derived: sum of 3 quarters · filed 2026-05-07 | -$5.88M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $588.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$2.94M derived: sum of 2 quarters · filed 2026-02-27 | -$10.27M derived: sum of 3 quarters · filed 2026-08-06 | -$22.42M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$3.53M 10-Q · filed 2025-11-06 | -$10.86M derived: sum of 2 quarters · filed 2026-08-06 | -$23.01M 10-Q · filed 2025-11-06 | -$5.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$7.33M 10-Q · filed 2026-08-06 | -$19.48M 10-Q · filed 2026-08-06 | -$1.50M derived: sum of 3 quarters · filed 2026-08-06 | -$36.03M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$12.15M 10-Q · filed 2026-05-07 | $5.83M derived: sum of 2 quarters · filed 2026-05-07 | -$28.70M derived: sum of 3 quarters · filed 2026-05-07 | -$28.86M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $17.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$16.54M derived: sum of 2 quarters · filed 2026-02-27 | -$16.71M derived: sum of 3 quarters · filed 2026-02-27 | -$1.17M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$34.52M 10-Q · filed 2025-11-06 | -$34.69M derived: sum of 2 quarters · filed 2025-11-06 | -$19.15M 10-Q · filed 2025-11-06 | -$56.40M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$170.00K 10-Q · filed 2025-08-07 | $15.37M 10-Q · filed 2025-08-07 | -$21.87M derived: sum of 3 quarters · filed 2026-02-27 | -$27.17M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $15.54M 10-Q · filed 2025-05-07 | -$21.70M derived: sum of 2 quarters · filed 2026-02-27 | -$27.00M derived: sum of 3 quarters · filed 2026-02-27 | -$18.68M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$37.25M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$42.54M derived: sum of 2 quarters · filed 2026-02-27 | -$34.23M derived: sum of 3 quarters · filed 2026-02-27 | -$48.50M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$5.29M 10-Q · filed 2024-11-12 | $3.02M derived: sum of 2 quarters · filed 2024-11-12 | -$11.25M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $8.31M 10-Q · filed 2024-08-09 | -$5.96M 10-Q · filed 2024-08-09 | ||
| 2023-03-31 | -$14.27M 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $97.06M 10-K · filed 2025-02-28 | |||
| 2021-12-31 | $42.43M 10-K · filed 2024-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |